MA28373A1 - Modulateurs furosemide de hm74 - Google Patents

Modulateurs furosemide de hm74

Info

Publication number
MA28373A1
MA28373A1 MA29295A MA29295A MA28373A1 MA 28373 A1 MA28373 A1 MA 28373A1 MA 29295 A MA29295 A MA 29295A MA 29295 A MA29295 A MA 29295A MA 28373 A1 MA28373 A1 MA 28373A1
Authority
MA
Morocco
Prior art keywords
furosemide
modulators
furosemide modulators
Prior art date
Application number
MA29295A
Other languages
English (en)
Inventor
Anne Minnich
Theresa Kuntzweiler
Haifeng Eishingdrelo
Michael Angelastro
Han-Jochen Lang
Original Assignee
Sanofi Aventis Deutschland
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland, Aventis Pharma Inc filed Critical Sanofi Aventis Deutschland
Publication of MA28373A1 publication Critical patent/MA28373A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/335—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
MA29295A 2004-02-20 2006-08-29 Modulateurs furosemide de hm74 MA28373A1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54601104P 2004-02-20 2004-02-20

Publications (1)

Publication Number Publication Date
MA28373A1 true MA28373A1 (fr) 2006-12-01

Family

ID=34910746

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29295A MA28373A1 (fr) 2004-02-20 2006-08-29 Modulateurs furosemide de hm74

Country Status (24)

Country Link
US (2) US7232811B2 (fr)
EP (1) EP1718292A1 (fr)
JP (1) JP2007523166A (fr)
KR (1) KR20060127141A (fr)
CN (1) CN1921845A (fr)
AR (1) AR047747A1 (fr)
AU (1) AU2005216879B2 (fr)
BR (1) BRPI0506792A (fr)
CA (1) CA2557444A1 (fr)
CR (1) CR8528A (fr)
EC (1) ECSP066777A (fr)
IL (1) IL177086A (fr)
MA (1) MA28373A1 (fr)
ME (1) MEP21108A (fr)
MX (1) MXPA06008612A (fr)
NO (1) NO20064237L (fr)
NZ (1) NZ548830A (fr)
RS (1) RS20060473A (fr)
RU (1) RU2006133540A (fr)
SG (1) SG164305A1 (fr)
TN (1) TNSN06234A1 (fr)
TW (1) TW200538109A (fr)
WO (1) WO2005082350A1 (fr)
ZA (1) ZA200606679B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008283B2 (en) 1998-12-23 2011-08-30 Neurotherapeutics Pharma, Inc. Methods and compositions for the treatment of neuropsychiatric disorders
EP1603585A2 (fr) * 2003-03-14 2005-12-14 Bristol-Myers Squibb Company Polynucleotide codant un nouveau variant de recepteur de hm74, hgprbmy74 couple a une proteine g humaine
NZ555320A (en) 2004-12-03 2010-11-26 Schering Corp Substituted piperazines as CB1 antagonists
MX2008008694A (es) * 2006-01-03 2009-01-07 Algebra Inc Compuestos conjugados de amina terapeutica-arilsulfonamida.
JP2009528266A (ja) * 2006-01-18 2009-08-06 シェーリング コーポレイション カンナビノイド受容体修飾因子
CA2669117A1 (fr) 2006-10-26 2008-05-02 Gary A. Flynn Modulateurs d'aquaporine et procedes pour leur utilisation pour le traitement d'un oedeme et d'un desequilibre de fluides
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
EP2170846A2 (fr) * 2007-06-28 2010-04-07 Intervet International BV Pipérazines à substitution servant d'antagonistes des récepteurs cb1
EP2170847A2 (fr) * 2007-06-28 2010-04-07 Intervet International BV Pipérazines à substitution servant d'antagonistes des récepteurs cb1
LT6401B (lt) * 2015-07-28 2017-06-12 Vilniaus Universitetas Karboanhidrazės selektyvūs inhibitoriai

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3875150A (en) 1969-04-29 1975-04-01 Leo Pharm Prod Ltd New sulfamyl-anthranilic acids
GB1260155A (en) * 1969-04-29 1972-01-12 Leo Pharm Prod Ltd Sulphonamido anthranilic acid derivatives
DE2206424A1 (de) * 1971-02-15 1972-08-24 Dumex Ltd As Verfahren zur Herstellung von N-substituierten Anthranilsäurederivaten
DE2247828A1 (de) * 1972-09-29 1974-04-04 Hoechst Ag Sulfamoyl-anthranilsaeuren und verfahren zu ihrer herstellung
DE2406972C3 (de) * 1974-02-14 1979-07-19 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von 5-Sulfamoylanthranilsäuren
DE2718871C3 (de) * 1977-04-28 1980-07-17 Hoechst Ag, 6000 Frankfurt N-(2-Furylmethyl)-5-sulfamoylorthanilsäuren und deren physiologisch verträgliche Salze und Verfahren zu ihrer Herstellung und ihre Verwendung bei der Bekämpfung von Oedemkrankheiten und Bluthochdruck
US4406896A (en) * 1979-12-20 1983-09-27 Merck & Co., Inc. Adjuvants for rectal delivery of drug substances
DE3006686A1 (de) * 1980-02-22 1981-08-27 Hoechst Ag, 6000 Frankfurt 5-sulfamoyl-orthanilsaeuren, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
DE3041812A1 (de) * 1980-11-06 1982-06-16 Hoechst Ag, 6000 Frankfurt Basisch substituierte 5-phenyltetrazole, verfahren zu ihrer herstellung und ihre verwendung als heilmittel
DE3101960A1 (de) * 1981-01-22 1982-09-02 Hoechst Ag, 6000 Frankfurt "basisch substituierte anthranilsaeuren, verfahren zu ihrer herstellung und ihre verwendung"
US5256687A (en) * 1985-09-09 1993-10-26 Hoechst Aktiengesellschaft Pharmaceutical composition for the treatment of high blood pressure
JPH0720862B2 (ja) * 1989-01-27 1995-03-08 ヘキスト・アクチエンゲゼルシヤフト 吸入用喘息治療剤
AU7966098A (en) * 1997-06-12 1998-12-30 Smithkline Beecham Corporation Hm74a receptor
GB0021484D0 (en) * 2000-09-01 2000-10-18 Boehringer Ingelheim Pharma Method for identifying substances which positively influence inflammatory conditions of chronic inflammatory airway diseases
DE10060809A1 (de) * 2000-12-07 2002-06-20 Aventis Pharma Gmbh Substituierte Anthranilsäuren, ihre Verwendung als Medikament oder Diagnostikum, sowie sie enthaltendes Medikament, sowie ein pharmazeutisches Kombinationspräparat mit einem Natrium/Wasserstoff-Austausch (NHE)-Blocker
US20030109673A1 (en) * 2002-10-04 2003-06-12 Xiao Yonghong Regulation of human hm74-like g protein coupled receptor

Also Published As

Publication number Publication date
US7556931B2 (en) 2009-07-07
IL177086A (en) 2010-06-16
AU2005216879A1 (en) 2005-09-09
RU2006133540A (ru) 2008-03-27
RS20060473A (en) 2008-08-07
TW200538109A (en) 2005-12-01
IL177086A0 (en) 2006-12-10
CR8528A (es) 2007-06-08
TNSN06234A1 (en) 2007-12-03
AU2005216879B2 (en) 2009-12-10
EP1718292A1 (fr) 2006-11-08
US20070213391A1 (en) 2007-09-13
MXPA06008612A (es) 2007-01-25
BRPI0506792A (pt) 2007-05-22
JP2007523166A (ja) 2007-08-16
NZ548830A (en) 2010-03-26
ZA200606679B (en) 2008-01-30
CN1921845A (zh) 2007-02-28
NO20064237L (no) 2006-09-19
CA2557444A1 (fr) 2005-09-09
WO2005082350A8 (fr) 2005-12-08
US7232811B2 (en) 2007-06-19
AR047747A1 (es) 2006-02-15
ECSP066777A (es) 2006-11-16
SG164305A1 (en) 2010-09-29
KR20060127141A (ko) 2006-12-11
US20050187280A1 (en) 2005-08-25
WO2005082350A1 (fr) 2005-09-09
MEP21108A (en) 2010-06-10

Similar Documents

Publication Publication Date Title
MA28373A1 (fr) Modulateurs furosemide de hm74
ATE540027T1 (de) Tetrahydroindazol-cannabinoidmodulatoren
DK1720866T3 (da) Fremgangsmåde
NO20050756D0 (no) Mikroelektromekaniske anordninger
DE602005012267D1 (de) N von geräten
DE602006004463D1 (de) Kristallform von asenapinmaleat
ATE456558T1 (de) Gabanerge modulatoren
ATE419193T1 (de) Verschlusskappe
DK2447252T3 (da) Theramuteinmodulatorer
ATE426604T1 (de) Spirocyclische cyclohexan-derivate
SE0501994L (sv) Styrningsutrustad cylinder
DE502005005196D1 (de) Direktional verfestigte bauteile
MA28368A1 (fr) Modulateurs oxydecahydronaphtalene de hm74
UA12345S (uk) Сувенір
DE502005007708D1 (de) Tropfenabscheideranordnung
FR2891181B1 (fr) Dispositf pour la fente de buches
FI20055133A0 (fi) Iskulaite
AT500549B8 (de) Klärbecken
DE602005000466D1 (de) Einwegverschlusskappe
FI20031581A0 (fi) Interferometri
FR2877833B1 (fr) Correcteur de lordoses
DE502004008171D1 (de) Viskosekupplung
FIU20050091U0 (fi) Hieromalaite
DE502005002684D1 (de) Dioxazinyl-substituierte thienylsulfonylaminocarbonylverbindungen
ATA13282004A (de) Massagegerät